Alprazolam
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Alprazolam: From Anxiety Disorder to Insomnia
One-Sentence Summary
Alprazolam is a benzodiazepine originally used to treat anxiety disorders and mixed anxiety and depressive disorder. The TxGNN model predicts it may be effective for insomnia (top-ranked prediction), but no clinical trials and only indirect literature currently support this direction. The strongest evidence in the data compiled for this report belongs to other predicted indications (agoraphobia and phobic disorder), which largely overlap with alprazolam's existing anxiolytic use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder; mixed anxiety and depressive disorder (the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, alprazolam is a benzodiazepine that enhances GABA-A receptor-mediated inhibition. This produces anxiolytic and sedative-hypnotic effects, so a mechanistic basis for treating insomnia is plausible.
Anxiety and insomnia frequently occur together, and sedation is already a recognised effect of the drug. However, the supplied literature is mostly indirect: a panic disorder review, pharmacokinetics, benzodiazepine utilisation, a COVID-19 insomnia survey, and zolpidem deprescribing. No study directly tests alprazolam for insomnia. Other benzodiazepines are already approved for insomnia, and the risks of dependence, falls and cognitive impairment weaken the case for repurposing alprazolam specifically.
Clinical Trial Evidence
Currently no related clinical trials registered for insomnia.
For context, one trial exists for another predicted indication, phobic disorder (rank 10), where alprazolam served only as a comparator:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00555139 | Phase 1 | Completed | 35 | Placebo- and alprazolam-controlled crossover study comparing the anxiolytic-like fMRI activity of GW876008 and GSK561679 in social anxiety disorder; alprazolam was an active comparator, not a direct efficacy test |
Literature Evidence
Literature for insomnia (selected from 18 items; none is an RCT of alprazolam for insomnia):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39183410 | 2024 | Observational (retrospective) | Medicine | Du Meridian moxibustion plus ear acupuncture compared with alprazolam in 116 patients with coronary heart disease and insomnia; alprazolam was the control treatment |
| 36692463 | 2023 | Meta-analysis | Acta Pharmaceutica | Tranquilizers in elderly patients with chronic non-communicable diseases: dose, outcomes and adverse effects |
| 23330992 | 2013 | Review | Expert Opin Drug Metab Toxicol | Pharmacokinetics of anxiolytic drugs |
| 7484706 | 1995 | Review | Am Fam Physician | Panic disorder overview (indirect relevance) |
| 37984023 | 2024 | Predictive/economic model | Value Health Reg Issues | Benzodiazepine use trends and economic burden; long-term use linked to memory loss, dependence and falls |
| 38363887 | 2024 | Cross-sectional | Medicine | Insomnia among COVID-19 survivors (no alprazolam data) |
| 35493764 | 2022 | Cohort | JHEP Reports | Zolpidem deprescribing reduces falls and fractures in cirrhosis (not alprazolam) |
| 37801512 | 2023 | Preclinical | Aging | Repeated alprazolam in mice caused mitochondrial dysfunction and impaired memory consolidation |
Stronger evidence exists for the related predicted indications of agoraphobia and phobic disorder. It includes a Cochrane network meta-analysis of pharmacological treatments for panic disorder (38014714, 2023), a meta-analysis of alprazolam versus other benzodiazepines (21869686, 2011), and several placebo-controlled RCTs, such as 3282478 (n≈526, 1988) and 8101126 (n=154, 1993). These mostly address panic disorder with agoraphobia, an area that overlaps with alprazolam's existing anxiolytic use.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN01984P | XANAX TABLET 0.25 mg | Tablet, film coated | Not recorded |
| SIN01985P | XANAX TABLET 0.5 mg | Tablet, film coated | Not recorded |
| SIN09173P | XANAX XR EXTENDED-RELEASE TABLET 0.5 mg | Tablet, sugar coated | Not recorded |
| SIN09175P | XANAX XR EXTENDED-RELEASE TABLET 1 mg | Tablet, sugar coated | Not recorded |
| SIN07871P | APO-ALPRAZ TABLET 0.5 mg | Tablet | Not recorded |
Two further licences are valid: SIN07872P (APO-ALPRAZ 0.25 mg) and SIN10458P (ZACETIN 0.25 mg). All 7 registrations are single-ingredient products.
Safety Considerations
- Contraindication signals (knowledge graph, not label text): kidney disease, liver disease, gallbladder disease, open-angle and angle-closure glaucoma, obesity disorders, obstructive sleep apnea and other sleep apnea syndromes, congenital central hypoventilation syndrome, and substance-related disorders or dependence.
- Drug Interactions: 100 interactions were identified. Examples:
- Major: morphine (including liposomal morphine), with additive central nervous system and respiratory depression.
- Moderate: aprepitant, bupropion, cimetidine, clarithromycin, clotrimazole, dronabinol, eliglustat, glycerol phenylbutyrate, metoclopramide, miconazole.
- Minor: antacids (aluminum hydroxide, calcium carbonate, magnesium salts), betamethasone, dexamethasone.
- Literature-based concerns: dependence, withdrawal and rebound on discontinuation, memory impairment, falls in older people, and a possible birth-defect signal with prenatal benzodiazepine exposure.
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: Insomnia is supported mainly by the model score and a plausible sedative mechanism. No trial directly tests alprazolam for insomnia, and approved alternatives exist. Known risks of dependence, falls and cognitive impairment further weaken the case. By contrast, agoraphobia and phobic disorder (both L1, Proceed with Guardrails) have stronger evidence, but they largely reflect established anxiolytic use rather than new repurposing.
To proceed, the following is needed:
- Controlled trial data on alprazolam for insomnia, ideally compared with approved hypnotics
- Mechanism of action data from DrugBank
- The Singapore package insert (warnings, contraindications and approved indications), which was not available
- A risk-benefit assessment covering dependence, withdrawal, falls and sedation, particularly in older patients and those with sleep apnea
- Dosage-form and route compatibility assessment for any new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.